Bleeding Disorder Screening, Awareness, and Further Education (SAFE) Act of 2011

Hemophilia research, prevention, surveillance and service programs and issues. HR1919 Bleeding Disorders Screening Awareness and Further Education Act of 2011

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

HR 1845/ S 960 Medicare IVIG Access Act; HR 2672/ S 1423 Preserving Access to Orphan Drugs Act; HR 1919 Bleeding Disorders Screening, Awareness and Further Education Act; HR 4209 Patients' Access to Treatments Act of 2012; pharmaceutical distribution and supply chain security issues; introductory visits to member offices who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1845 & S. 960: Medicare IVIG Access Act H.R. 1919: Bleeding Disorder Screening, Awareness & Further Education Act H.R. 2672 / S 1423: Preserving Access to Orphan Drugs Act Introductory/Educational meetings with Congressional offices H.R. 4209: Patients Access to Treatment Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Hemophilia research, prevention, surveillance and service programs and issues. HR1919 Bleeding Disorders Screening Awareness and Further Education Act of 2011

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

HR 1845 / S 960 Medicare IVIG Access Act HR 2672 / S 1423 Preserving Access to Orphan Drugs Act HR 1919 Bleeding Disorders Screening Awareness and Further Education Act Introductory visits to member offices who represent districts where Grifols has a facility S.3187 Food and Drug Administration Safety and Innovation Act; Drug Shortages Reporting Provisions H.R.4209 Patients' Access to Treatments Act of 2012

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1845 & S. 960: Medicare IVIG Access Act H.R. 1919: Bleeding Disorder Screening, Awareness & Further Education Act H.R. 2672: Preserving Access to Orphan Drug Act Introductory/Educational meetings with Congressional offices

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Hemophilia research, prevention, surveillance and service programs and issues. HR1919 Bleeding Disorders Screening Awareness and Further Education Act of 2011

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

HR 1845 / S 960 Mediare IVIG Access Act HR 2672 / S 1423 Preserving Access to Orphan Drugs Act Proposed Prescription Drug Shortage Legislation Public Health Service Pricing Program under Section 340B of the Public Health Service Act Medicaid Outpatient Prescription Drug - Average Manufacturer Price Proposed Regulations HR 1919 Bleeding Disorders Screening Awareness and Further Education Act General Legislative visits to member offices where who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

HR 1845 / S 960 Mediare IVIG Access Act HR 2672 / S 1423 Preserving Access to Orphan Drugs Act Proposed Prescription Drug Shortage Legislation Public Health Service Pricing Program under Section 340B of the Public Health Service Act Medicaid Outpatient Prescription Drug - Average Manufacturer Price Proposed Regulations HR 1919 Bleeding Disorders Screening Awareness and Further Education Act General Legislative visits to member offices where who represent districts where Grifols has a facility

Client expense: Not reported · Firm income: $350,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

HR 1845 / S 960 Medicare IVIG Access Act; HR 2672 / S1423 Preserving Access to Orphan Drugs Act Proposed Prescription Drug Shortage Legislation Public Health Service Pricing Program under Section 340B Medicaid Outpatient Prescription Drug/Average Manufacturer Price Proposed Rule HR 1919 Bleeding Disorder Screening Awareness and Further Education Act General Legislative visits to member offices who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

HR 1845 / S 960 Medicare IVIG Access Act; HR 2672 / S 1423 Preserving Access to Orphan Drugs Act Proposed Prescription Drug Shortage Legislation Public Health Service Pricing Program under Section 340b Medicaid Outpatient Prescription Drug / Average Manufacturer Price Proposed Rule HR 1919 Bleeding Disorders Screening Awareness and Further Education Act General Legislative visits to member offices who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

HR 1845 / S 960 Medicare IVIG Access Act; HR 2672 / S 1423 Preserving Access to Orphan Drugs Act Proposed Prescription Drug Shortage Legislation Public Health Service Pricing Program under Section 340B Medicaid Outpatient Prescription Drug/Average Manufacturer Price Proposed Rule HR 1919 Bleeding Disorder Screening Awareness and Further Education Act General Legislative visits to member offices who represent districts where Grifols has a facility

Client expense: $350,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

H.R. 1845 & S. 960: Medicare IVIG Access Act H.R. 1919: Bleeding Disorder Screening, Awareness, & Further Education Act H.R. 2672: Preserving Access to Orphan Drug Act Introductory/Educational meetings with Congressional offices

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Hemophilia research, prevention, surveillance and service programs and issues. HR1919 Bleeding Disorders Screening Awareness and Further Education Act of 2011

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE

Wilderness, public land management, S. 979, H.R. 1919, H.R. 1581, H.R. 2147

Client expense: Not reported · Firm income: Not reported

Government targets: Bureau of Land Management (BLM), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE

HR 1845 / S 960 Medicare IVIG Access Act Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Public Health Service Pricing Program under Section 340B Healthcare deficit reduction proposals HR 1919 Bleeding Disorder Screening Awareness and Further Education Act General Legislative visits to member offices who represent districts where Grifols has a facility

Client expense: $375,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE

HR 1845 & S 960: Medicare IVIG Access Act HR 1919: Bleeding Disorder Screening, Awareness, and Further Education Act Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Acquisition of Talecris by GRIFOLS, Educational meetings with Congressional offices

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare patient IVIG Access Legislation Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Pending acquisition of Talecris by Grifols. Educational meetings with Congressional offices HR 4: Comprehensive 1099 Taxpayer Protection & Repayment of Exchange Subsidy Overpayments Act HR 1919: Bleeing Disorder Screening, Awareness, and Further Education Act

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1845 & S 960: Medicare IVIG Access Act HR 1919: Bleeding Disorder Screening, Awareness, and Further Education Act Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Pending acquisition of Talecris by GRIFOLS, Educational meetings with Congressional offices Nomination to HHS Advisory Committee on Blood Safety and Availability

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare patient IVIG Access Legislation Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Pending acquisition of Talecris by Grifols. Educational meetings with Congressional offices HR 4: Comprehensive 1099 Taxpayer Protection & Repayment of Exchange Subsidy Overpayments Act HR 1919: Bleeing Disorder Screening, Awareness, and Further Education Act

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1845 / S 960: Medicare IVIG Access Act HR 1919: Bleeding Disorder Screening, Awareness, and Further Education Act Pharmaceutical Industry Annual Fee; Orphan Drug Exclusion Pending acquisition of Talecris by GRIFOLS, Educational meetings with Congressional offices Nomination to HHS Advisory Committee on Blood Safety and Availability

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE